SpA-Associated IBD — RACP Adult Medicine MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: E — Crohn's disease (new diagnosis, potentially unmasked)
Approximately 5–10% of patients with ankylosing spondylitis develop inflammatory bowel disease (IBD), most commonly Crohn's disease. Subclinical gut inflammation is present in up to 60% of SpA patients. The patchy inflammation with granulomas is consistent with Crohn's disease. Importantly, adalimumab is already used for both SpA and Crohn's disease, so it should be continued (it treats both conditions). This is NOT drug-induced colitis. The IBD may have been subclinical before diagnosis.
Reference: eTG – 2025 – Rheumatology; eTG – 2025 – Gastrointestinal; ECCO – 2024